[en] AIMS: This study was undertaken to determine the effects of a short-term dexamethasone treatment on hepatic sensitivities to insulin and glucagon. METHODS: Eleven healthy subjects were studied during one or several of four protocols. In all protocols, somatostatin was infused continuously to inhibit pancreatic hormone secretion. In protocol 1, basal insulin was infused over 300 min while glucagon was infused at a rate of 0.5 mg/kg(-1)/min(-1)during 180 min, then at a rate of 1.5 ng/kg(-1)/min(-1)during 150 min. In protocol 2, the same experiment was performed after a 2 day treatment with 8 mg/day dexamethasone. In protocol 3, the two-step glucagon infusion was performed during insulin infusion at a rate aimed to reproduce the hyperinsulinemia observed during protocol 2. In protocol 4, continuous basal insulin and low glucagon (0.5 mg/kg(-1)/min(-1)) were infused over 330 min. RESULTS: In protocol 1, plasma glucose rose transiently by 2.0 +/- 0.3 mmol/l when the glucagon rate was increased and glucose production increased by 1.4 +/- 0.5 micromol/kg(-1)/min(-1). In protocol 2, the insulin infusion rate (1.85 +/- 0.36 nmol/kg(-1)/min(-1)) required to maintain glycemia was 3.3-fold higher than during protocol 1. Glucagon-induced stimulation of glycemia (by 1.47 +/- 0.5 mmol/l) and endogenous glucose production (by 0.8 +/- 0.3 micromol/kg(-1)/min(-1)) were blunted, but not abolished. In protocol 3, endogenous glucose production was suppressed by 75% by hyperinsulinemia and was not stimulated when the glucagon infusion rate was increased. In protocol 4, endogenous glucose production did not change significantly with time. CONCLUSION: These results indicate that high dose glucocorticoids induce a marked hepatic insulin resistance. Stimulation of glucose production by hyperglucagonemia was maintained in spite of hyperinsulinemia which can be attributed to either hepatic insulin resistance and/or increased hepatic glucagon sensitivity.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Dirlewanger, M.
Schneiter, P. H.
Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Jequier, E.
Rey, V.
Tappy, L.
Language :
English
Title :
Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man.
Gerich J E. Control of glycaemia. Baillieres Clin Endocrinol Metab 1993; 7: 551-586
DeFronzo R A. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687
Cherrington A D. The metabolic actions of glucagon. In: Draznin B, Rizza R, eds. Clinical Research in Diabetes and Obesity. Totowa: Humana Press, 1997: 221-242
Cherrington A D, Liljenquist J E, Shulman G I, Williams P E, Lacy W W. Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol 1979; 236: E263-E271
Liljenquist J E, Mueller G L, Cherrington A D et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977; 59: 369-374
Holste L C, Connolly C C, Moore M C, Neal D W, Cherrington A D. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 1997; 273: E488-E496
Shulman G I, Liljenquist J E, Williams P E, Lacy W W, Cherrington A D. Glucose disposal during insulinopenia in somatostatin-treated dogs: the roles of glucose and glucagon. J Clin Invest 1978; 62: 487-491
Dinneen S F. The effects of glucocorticoid hormones on substrate metabolism. In: Draznin B, Rizza R, eds. Clinical Research in Diabetes and Obesity. Totowa: Humana Press, 1997: 243-258
Dinneen S, Alzaid A, Miles J, Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 1993; 92: 2283-2290
Geley S, Fiegl M, Hartmann B L, Kofler R. Genes mediating glucocorticoid effects and mechanisms of their regulation. Rev Physiol Biochem Pharmacol 1996; 128: 1-97
De Wulff H, Hers H. The stimulation of glycogen synthesis and of glycogen synthase in the liver by glucocorticoids. Eur J Biochem 1967; 2: 57-60
Rizza R, Mandarino L, Gerich J. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131-138
Wajngot A, Khan A, Giacca A, Vranic M, Efendic S. Dexamethasone increases glucose cycling, but not glucose production in healthy subjects. Am J Physiol 1990; 259: E626-E632
Lecavalier L, Bolli G, Gerich J. Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans. Am J Physiol 1990; 258: E569-E575
Finegood D T, Bergman R N, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic euglycemic glucose clamps: comparison of labelled and unlabelled glucose infusates. Diabetes 1987; 36: 914-924
Tappy L, Dussoix P, lynedjian P et al. Abnormal regulation of hepatic glucose output in maturity onset diabetes of the young caused by a specific mutation of the glucokinase gene. Diabetes 1997; 46: 204-208
Wolfe R R. Radioactive and Stable Isotope Tracers in Biomedicine. New York: Wiley-Liss, 1992
Ferrannini E, DeFronzo R A, Sherwin R S. Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 1982; 242: E73-E81
Bomboy J D, Lewis S B, Lacy W W, Sinclair-Smith B C, Liljenquist J E. Transient stimulatory effect of sustained hyperglucagonemia on splanchnic glucose production in normal and diabetic man. Diabetes 1977; 26: 177-184
Cherrington A D, Diamond M P, Green D R, Williams P E. Evidence for an intrahepatic contribution to the waning effect of glucagon on glucose production in the conscious dog. Diabetes 1982; 31: 917-922
Magnusson I, Rothman D L, Gerard D P, Katz L E, Shulman G I. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 1995; 44: 185-189
Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 1992; 89: 6035-6039
Schneller P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol 1998; 275: E806-E813
Fernandez-Mejia C, Davidson M B. Regulation of glucokinase and proinsulin gene expression and insulin secretion in RIN-m5F cells by dexamethasone, retinoic acid, and thyroid hormone. Endocrinology 1992; 130: 1660-1668
Baron A D, Wallace P, Brechtel G. In vivo regulation of non-insulin-mediated and insulin-mediated glucose uptake by cortisol. Diabetes 1987; 36: 1230-1237
Tappy L, Randin D, Vollenweider P et al. Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 1994; 79: 1063-1069
Cherrington A D, Williams P E, Shulman G I, Lacy W W. Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 1981; 30: 180-187
Goldstein R E, Wasserman D H, McGuinness O P, Brooks Lacy D, Cherrington A D, Abumrad N N. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am J Physiol 1993; 264: E119-E127
Stalmans W, Bollen M, Mvumbi L. Control of glycogen synthesis in health and disease. Diabetes Metab Rev 1987; 3: 127-161